Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
← catalyst calendarNCT07494305 · readout ≤ 559 d
Sponsored by LB Pharmaceuticals Inc. (industry) · LBRX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
320estimated
Sites
26
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-23 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bipolar I Disorder
Interventions
- Drug: LB-102
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Montgomery Åsberg Depression Rating -10 core symptom scale (MADRS-10)
measured Baseline to Day 42
Permalink · LBRX's whole pipeline · Catalyst calendar · Every registered study · What changed